Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific.
Cancer disparities
Clinical trial enrollment
Endocrine cancer
Health disparities
Parity
Journal
American journal of surgery
ISSN: 1879-1883
Titre abrégé: Am J Surg
Pays: United States
ID NLM: 0370473
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
04
07
2018
revised:
21
01
2019
accepted:
12
02
2019
pubmed:
14
3
2019
medline:
17
1
2020
entrez:
14
3
2019
Statut:
ppublish
Résumé
We sought to assess participation of underrepresented minorities with endocrine neoplasms in clinical trials conducted in the National Cancer Institute's (NCI) Intramural Research Program. We performed a retrospective analysis of patients enrolled in Endocrine Oncology Branch (EOB) clinical trials, comparing demographics to regional and national demographics. We compared specific endocrine cancer patient data to data from NCI's Surveillance, Epidemiology, and End Results (SEER) program. Comparing EOB patients to national demographics, we found more white (77% vs 74%, P < 0.001) and black patients (14% vs 12%, P < 0.001). For thyroid cancer, there were more black (16% vs 7%, P < 0.0001) and other minority patients (17% vs 11%, P < 0.0001) compared to SEER. For gastroenteropancreatic neuroendocrine tumors (GEPNETs), there were fewer black (6% vs 19%, P < 0.0001) and other minority patients (6% vs 8%, P < 0.0001). Enrollment parity of underrepresented minorities into clinical trials is achievable, although possibly cancer type-specific.
Sections du résumé
BACKGROUND
We sought to assess participation of underrepresented minorities with endocrine neoplasms in clinical trials conducted in the National Cancer Institute's (NCI) Intramural Research Program.
METHODS
We performed a retrospective analysis of patients enrolled in Endocrine Oncology Branch (EOB) clinical trials, comparing demographics to regional and national demographics. We compared specific endocrine cancer patient data to data from NCI's Surveillance, Epidemiology, and End Results (SEER) program.
RESULTS
Comparing EOB patients to national demographics, we found more white (77% vs 74%, P < 0.001) and black patients (14% vs 12%, P < 0.001). For thyroid cancer, there were more black (16% vs 7%, P < 0.0001) and other minority patients (17% vs 11%, P < 0.0001) compared to SEER. For gastroenteropancreatic neuroendocrine tumors (GEPNETs), there were fewer black (6% vs 19%, P < 0.0001) and other minority patients (6% vs 8%, P < 0.0001).
CONCLUSION
Enrollment parity of underrepresented minorities into clinical trials is achievable, although possibly cancer type-specific.
Identifiants
pubmed: 30862353
pii: S0002-9610(18)30734-7
doi: 10.1016/j.amjsurg.2019.02.019
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-17Informations de copyright
Copyright © 2019. Published by Elsevier Inc.